Stock Events

TG Therapeutics 

€16.3
8
+€3.39+26.22% Wednesday 20:42

Statistics

Day High
16.61
Day Low
12.44
52W High
-
52W Low
-
Volume
8,920
Avg. Volume
-
Mkt Cap
2.02B
P/E Ratio
-77.85
Dividend Yield
-
Dividend
-

Earnings

28FebConfirmed
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-0.51
-0.1
0.32
0.73
Expected EPS
-0.1
Actual EPS
-0.09

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NKB2.F. It's not an investment recommendation.

Analyst Ratings

32.33Average Price Target
The highest estimate is €45.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
Show more...
CEO
Mr. Michael S. Weiss Esq.
Employees
245
Country
US
ISIN
US88322Q1085
WKN
000A1JXW7

Listings